Evidence map›Paper›PMID 35803384›Full record

ArticleThe Journal of infection2022

Immunogenicity of a third dose of inactivated COVID-19 vaccine in people living with HIV-1, HBV, and tuberculosis during the Omicron variant epidemic: A cross-sectional study.

Yan Yan, Chantsalmaa Davgadorj, Chunyan Lyu, Shiliang Zhang, Yuanwang Qiu

Abstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of infection, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Yan YanCenter of Clinical Laboratory, The Fifth People's Hospital of Wuxi, Affiliated Hospital of Jiangnan University, Wuxi, China; The International Joint Research Laboratory for Infection and Immunity (China-Germany), Jiangnan University, Wuxi, China; Hepatology Institute of Wuxi, The Fifth People's Hospital of Wuxi (Wuxi Infectious Disease Hospital), Affiliated Hospital of Jiangnan University, Wuxi, China.
Chantsalmaa DavgadorjCenter of Clinical Laboratory, The Fifth People's Hospital of Wuxi, Affiliated Hospital of Jiangnan University, Wuxi, China; The International Joint Research Laboratory for Infection and Immunity (China-Germany), Jiangnan University, Wuxi, China.
Chunyan LyuCenter of Clinical Laboratory, The Fifth People's Hospital of Wuxi, Affiliated Hospital of Jiangnan University, Wuxi, China.
Shiliang ZhangCenter of Clinical Laboratory, The Fifth People's Hospital of Wuxi, Affiliated Hospital of Jiangnan University, Wuxi, China. Electronic address: 136561987282@163.com.
Yuanwang QiuThe International Joint Research Laboratory for Infection and Immunity (China-Germany), Jiangnan University, Wuxi, China; Hepatology Institute of Wuxi, The Fifth People's Hospital of Wuxi (Wuxi Infectious Disease Hospital), Affiliated Hospital of Jiangnan University, Wuxi, China. Electronic address: 306126019@qq.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

COVID-19HIV-1HIV SeropositivityTuberculosisAntibodies, ViralCOVID-19 VaccinesCross-Sectional StudiesHepatitis B virusHumansImmunogenicity, VaccineSARS-CoV-2Antibodies, ViralCOVID-19 VaccinesCoronavirus disease 2019 (COVID-19)HBVHIV-1Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)TuberculosisVaccine

Identifiers

PMID35803384
PMCPMC9254457

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.